Praxis Stock Target Raised Amid Analyst Divergence
Wedbush raised Praxis Precision Medicines' price target to $95 on Jan. 12, maintaining an Underperform rating despite a recent $621M offering. Wall Street consensus remains Strong Buy.
Topic
Latest reporting and analysis tagged with FDA applications.
Wedbush raised Praxis Precision Medicines' price target to $95 on Jan. 12, maintaining an Underperform rating despite a recent $621M offering. Wall Street consensus remains Strong Buy.